Cargando…

1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints

BACKGROUND: Missing or incomplete phenotypic information can severely deteriorate the statistical power in epidemiological studies. High-throughput quantification of small-molecules in bio-samples, i.e. ‘metabolomics’, is steadily gaining popularity, as it is highly informative for various phenotypi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bizzarri, D., Reinders, M.J.T., Beekman, M., Slagboom, P.E., BBMRI-NL, van den Akker, E.B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703237/ https://www.ncbi.nlm.nih.gov/pubmed/34942446 http://dx.doi.org/10.1016/j.ebiom.2021.103764

Ejemplares similares

MiMIR: R-shiny application to infer risk factors and endpoints from Nightingale Health’s (1)H-NMR metabolomics data
por: Bizzarri, D, et al.
Publicado: (2022)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint
por: Nixon, Richard M, et al.
Publicado: (2003)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Metabolomic predictors of phenotypic traits can replace and complement measured clinical variables in population-scale expression profiling studies
por: Niehues, Anna, et al.
Publicado: (2022)

Epigenetic and Metabolomic Biomarkers for Biological Age: A Comparative Analysis of Mortality and Frailty Risk
por: Kuiper, Lieke M, et al.
Publicado: (2023)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation
por: Naesens, Maarten, et al.
Publicado: (2022)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

The effect of standardized food intake on the association between BMI and (1)H-NMR metabolites
por: Schutte, Bianca A. M., et al.
Publicado: (2016)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
por: Ciani, Oriana, et al.
Publicado: (2023)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
por: Bikdeli, Behnood, et al.
Publicado: (2017)

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints
por: Pitcher, Alex, et al.
Publicado: (2011)

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

A call for better reporting of trials using surrogate primary endpoints
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Opening the Random Forest Black Box of (1)H NMR Metabolomics Data by the Exploitation of Surrogate Variables
por: Wenck, Soeren, et al.
Publicado: (2023)

Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project
por: Eastell, Richard, et al.
Publicado: (2021)

Differential insulin sensitivity of NMR-based metabolomic measures in a two-step hyperinsulinemic euglycemic clamp study
por: Wang, Wenyi, et al.
Publicado: (2021)

First do no harm: surrogate endpoints and the lesson of β-agonists in acute lung injury
por: Lakshminarayana, Pradeep H, et al.
Publicado: (2012)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u2s3dqae375irgi87ropfsf3rn